CAS 1609281-86-8

Formule : C21H23N5O4S

InChI : InChI=1S/C21H23N5O4S/c1-10-18(11(2)30-26-10)12-3-4-14(16(7-12)29-13-5-6-24-9-13)17-8-15(19(22)27)20(31-17)25-21(23)28/h3-4,7-8,13,24H,5-6,9H2,1-2H3,(H2,22,27)(H3,23,25,28)/t13-/m0/s1

Code InChI : NMFIXEFNQPDISY-ZDUSSCGKSA-N

SMILES : CC1=C(C(=NO1)C)C2=CC(=C(C=C2)C3=CC(=C(S3)NC(=O)N)C(=O)N)O[C@H]4CCNC4

AZD3264

CAS : 1609281-86-8

AZD3264

Formule : C₂₁H₂₃N₅O₄S

Degré de pureté : 99%

Masse moléculaire : 441.5

Ref: 54-BUP07115

2-[(Aminocarbonyl)amino]-5-[4-(3,5-dimethyl-4-isoxazolyl)-2-[(3S)-3-pyrrolidinyloxy]phenyl]-3-thiophenecarboxamide

CAS : 1609281-86-8

Formule : C₂₁H₂₃N₅O₄S

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 441.5034

Ref: IN-DA00ABN0

AZD3264

CAS : 1609281-86-8

AZD3264 is a new type IKK2 inhibitor.

Formule : C₂₁H₂₃N₅O₄S

Degré de pureté : 98.98% - 99.17%

Couleur et forme : Solid

Masse moléculaire : 441.503

Ref: TM-T6771

AZD3264

CAS : 1609281-86-8

Degré de pureté : 98%

Masse moléculaire : 441.147

Ref: 10-F870106

AZD3264

CAS : 1609281-86-8

AZD3264 is a matrix effect-based drug candidate that is currently being studied for its potential use in the treatment of chronic pulmonary diseases. The compound was synthesized by scalable synthesis and purified by chromatographic techniques. AZD3264 has been shown to have an effective dose against cancer cells in vitro and in vivo. It also has stem cell-like properties, which may make it more effective in regenerative therapies.

Formule : C₂₁H₂₃N₅O₄S

Degré de pureté : Min. 95%

Masse moléculaire : 441.5 g/mol

Ref: 3D-JPC28186